
Home » OCERA THERAPEUTICS, INC. RAISES $12 MILLION SERIES B FINANCING
OCERA THERAPEUTICS, INC. RAISES $12 MILLION SERIES B FINANCING
Ocera Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of clinical candidates for the treatment of gastrointestinal and liver diseases announced today that it has raised a $12 million Series B financing. The financing
will be used to continue clinical development of the company's first product,
AST-120. A pivotal Phase III clinical trial for AST-120 was initiated in the first
quarter of 2006 for the treatment of fistulizing Crohn's disease. The Series B
round was led by new investor, Sofinnova Ventures. Previous investors, Domain
Associates, LLC and Thomas, McNerney & Partners, LLC also participated in
this financing.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
08Feb
-
09Feb
-
15Feb
-
16Feb
-
22Feb
-
07Mar